HUP0105001A2 - PDE-IV gátló aktivitással rendelkező fenil-fenantridinek és ezeket tartalmazó gyógyszerkészítmények - Google Patents
PDE-IV gátló aktivitással rendelkező fenil-fenantridinek és ezeket tartalmazó gyógyszerkészítményekInfo
- Publication number
- HUP0105001A2 HUP0105001A2 HU0105001A HUP0105001A HUP0105001A2 HU P0105001 A2 HUP0105001 A2 HU P0105001A2 HU 0105001 A HU0105001 A HU 0105001A HU P0105001 A HUP0105001 A HU P0105001A HU P0105001 A2 HUP0105001 A2 HU P0105001A2
- Authority
- HU
- Hungary
- Prior art keywords
- group
- alkyl
- hydrogen atom
- aryl
- alkoxy
- Prior art date
Links
- SKHUPKIELOSDON-UHFFFAOYSA-N 1-phenylphenanthridine Chemical class C1=CC=CC=C1C1=CC=CC2=NC=C(C=CC=C3)C3=C12 SKHUPKIELOSDON-UHFFFAOYSA-N 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 10
- -1 1-piperedinyl Chemical group 0.000 abstract 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 9
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 5
- 125000003118 aryl group Chemical group 0.000 abstract 5
- 229910052799 carbon Inorganic materials 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 3
- 125000004981 cycloalkylmethyl group Chemical group 0.000 abstract 3
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 229910052731 fluorine Inorganic materials 0.000 abstract 2
- 239000011737 fluorine Substances 0.000 abstract 2
- 125000001153 fluoro group Chemical group F* 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 125000003830 C1- C4 alkylcarbonylamino group Chemical group 0.000 abstract 1
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical group [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 abstract 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000005530 alkylenedioxy group Chemical group 0.000 abstract 1
- 125000005129 aryl carbonyl group Chemical group 0.000 abstract 1
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 abstract 1
- KZNICNPSHKQLFF-UHFFFAOYSA-N dihydromaleimide Natural products O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/10—Aza-phenanthrenes
- C07D221/12—Phenanthridines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Transplantation (AREA)
- Toxicology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
Abstract
Az (I) ltal nos képletű 6-fenil-fenantidinek (mely képletben R1jelentése hidroxil-, 1-4 szénatomos alkoxi-, 3-7 szénatomoscikloalkoxi-, 3-7 szénatomos cikloalkil-metoxicsoport vagy fluorralteljesen vagy túlnyomórészt helyettesített 1-4 szénatomosalkoxicsoport; R2 jelentése hidroxil-, 1-4 szénatomos alkoxi-, 3-7szénatomos cikloalkoxi-, 3-7 szénatomos cikloalkil-metoxicsoport vagyfluorral teljesen vagy túlnyomórészt helyettesített 1-4 szénatomosalkoxicsoport; vagy R1 és R2 együtt 1-2 szénatomosalkiléndioxicsoportot képez; R3 jelentése hidrogénatom vagy 1-4szénatomos alkilcsoport; R31 jelentése hidrogénatom vagy 1-4szénatomos alkilcsoport vagy R3 és R31 együtt 1-4 szénatomosalkiléncsoportot képez; R4 jelentése hidrogénatom vagy 1-4 szénatomosalkilcsoport; R5 jelentése hidrogénatom; R51 jelentése hidrogénatom;vagy R5 és R51 együtt tov bbi k"tést képez; R6 jelentése O-R7, -S-R8,-C(O)-R9, -CH2-R10, -S(O)2-aril, -O-S(O)2-R11, pirrolidin-1-il,pirrolidin-1-il-2-on, pirrolidin-1-il-2,5-dion, piperedin-l-il,piperedin-l-il-2-on vagy piperedin-1-il-2,6-dioncsoport, ahol R7jelentése 3-7 szénatomos cikloalkil-, 3-7 szénatomos cikloalkil-metil-, 1-4 szénatomos alkoxi-(1-4 szénatomos alkil)-, aril- vagyfenil-(1-4 szénatomos alkil)-csoport; R8 jelentése hidrogénatom, 1-4szénatomos alkil-, 1-4 szénatomos alkil-karbonil-, aril-karbonil-,trifluorrmetil-, difluor-metil-, triklór-metil- vagy fenilcsoport; R9jelentése 1-4 szénatomos alkil-, 3-7 szénatomos cikloalkil-, 3-7szénatomos cikloalkil-metil-, 1-pirrolidinil-, 1-piperedinil-, 1-piperazinil-, 4-metil-piperazinil-, 4-morfolinil- vagy arilcsoport;R10 jelentése hidroxilcsoport, halogénatom, ciano-, karboxil-, 1-4szénatomos alkoxi-, fenoxi-, 1-4 szénatomos alkoxi-karbonil-, amino-karbonil-, mono- vagy di-(1-4 szénatomos alkil)-amino-karbonil-, -N(R15)R16 vagy 1-4 szénatomos alkil-karbonil-aminocsoport és R11jelentése 1-4 szénatomos lkíl-, amino-, mono- vagy di-(1-4 szénatomosalkil)-amino- vagy arilcsoport; aril jelentése fenil-, piridil- vagyhelyettesített fenilcsoport; R13 jelentése hidrogénatom,hidroxilcsoport, halogénatom, ciano-, nitro-, amino-, 1-4 szénatomosalkil-, trifluor-metil-, 1-4 szénatomos alkoxicsoport fluorralhelyettesített 1-4 szénatomos alkoxicsoport, fenil-, fenil-(1-4szénatomos alkil)-csoport, -C(O)-OR14, -C(O)-N(R15)R16, -N(R17)R18, -S(O)2-R19, -S(O)2-N(R15)R16 csoport vagy valamely, R6 értelmezésénélmegadott csoport; R14, R15 és R16 jelentése hidrogénatom, 1-4szénatomos alkil-, 3-7 szénatomos cikloalkil-, 3-7 szénatomoscikloalkil-metil- vagy arilcsoport; vagy R15 és R16 a nitrogénatommalegyütt, amelyhez kapcsolódik, 5-7 tagú gyűrűt képez; R17 jelentésehidrogénatom, 1-4 szénatomos alkil-, -S(O)2 (1-4 szénatomos alkil vagy-S(O)2-arilcsoport; R18 jelentése 1-4 szénatomos a
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99100694 | 1999-01-15 | ||
| PCT/EP2000/000172 WO2000042020A1 (en) | 1999-01-15 | 2000-01-12 | Phenylphenanthridines with pde-iv inhibiting activity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| HUP0105001A2 true HUP0105001A2 (hu) | 2002-04-29 |
| HUP0105001A3 HUP0105001A3 (en) | 2002-10-28 |
| HU227624B1 HU227624B1 (en) | 2011-09-28 |
Family
ID=8237351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0105001A HU227624B1 (en) | 1999-01-15 | 2000-01-12 | Phenylphenanthridines with pde-iv inhibiting activity and medicaments containing them |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US6476025B1 (hu) |
| EP (2) | EP1147089B1 (hu) |
| JP (1) | JP4653314B2 (hu) |
| KR (1) | KR100720906B1 (hu) |
| CN (1) | CN1152864C (hu) |
| AT (1) | ATE312081T1 (hu) |
| AU (1) | AU774868B2 (hu) |
| BG (1) | BG65126B1 (hu) |
| BR (1) | BR0007527B1 (hu) |
| CA (1) | CA2359440C (hu) |
| CY (1) | CY1106436T1 (hu) |
| CZ (1) | CZ300366B6 (hu) |
| DE (1) | DE60024581T2 (hu) |
| DK (1) | DK1147089T3 (hu) |
| EA (1) | EA003780B1 (hu) |
| EE (1) | EE05105B1 (hu) |
| ES (1) | ES2254132T3 (hu) |
| HK (1) | HK1040997B (hu) |
| HR (1) | HRP20010578A2 (hu) |
| HU (1) | HU227624B1 (hu) |
| ID (1) | ID29070A (hu) |
| IL (2) | IL144026A0 (hu) |
| NO (1) | NO320182B1 (hu) |
| NZ (1) | NZ512872A (hu) |
| PL (1) | PL205670B1 (hu) |
| RS (1) | RS50297B (hu) |
| SI (1) | SI1147089T1 (hu) |
| SK (1) | SK286946B6 (hu) |
| TR (2) | TR200101938T2 (hu) |
| UA (1) | UA69436C2 (hu) |
| WO (1) | WO2000042020A1 (hu) |
| ZA (1) | ZA200104864B (hu) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002006238A1 (en) * | 2000-07-14 | 2002-01-24 | Altana Pharma Ag | Cycloalkyl - or cycloalkylmethyl-substituted 6-phenylphenanthridines |
| CA2495597A1 (en) * | 2002-08-17 | 2004-03-04 | Altana Pharma Ag | Novel phenanthridines |
| EP1539164B1 (en) | 2002-08-29 | 2006-12-20 | ALTANA Pharma AG | 2-hydroxy-6-phenylphenanthridines as pde-4 inhibitors |
| DE60311662T2 (de) | 2002-08-29 | 2007-10-25 | Altana Pharma Ag | 3-hydroxy-6-phenylphenanthridine als pde-4 inhibitoren |
| US6894061B2 (en) | 2002-12-04 | 2005-05-17 | Wyeth | Substituted dihydrophenanthridinesulfonamides |
| JP2007500685A (ja) * | 2003-07-31 | 2007-01-18 | アルタナ ファルマ アクチエンゲゼルシャフト | 新規の６−フェニルフェナントリジン |
| CA2533636A1 (en) * | 2003-07-31 | 2005-02-10 | Altana Pharma Ag | Novel 6-phenylphenanthridines |
| AU2004269923B2 (en) * | 2003-09-05 | 2010-05-13 | Takeda Gmbh | Use of PDE4 inhibitors for the treatment of diabetes mellitus |
| EP1720835B1 (en) | 2004-02-18 | 2012-12-12 | Nycomed GmbH | Novel guanidinyl-substituted hydroxy-6-phenylphenanthridines as effective phosphodiesterase (pde) 4 inhibitors |
| AR049419A1 (es) * | 2004-03-03 | 2006-08-02 | Altana Pharma Ag | Hidroxi-6-fenilfenantridinas sustituidas con heterociclilo |
| SG182194A1 (en) | 2004-03-03 | 2012-07-30 | Nycomed Gmbh | Novel hydroxy-6-heteroarylphenanthridines and their use as pde4 inhibitors |
| EP1745025A2 (en) * | 2004-03-09 | 2007-01-24 | Altana Pharma AG | Novel isoamido-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors |
| AU2005221831A1 (en) * | 2004-03-10 | 2005-09-22 | Nycomed Gmbh | Novel thio-containing hydroxy-6-phenylphenanthridines and their use as PDE4 inhibitors |
| CA2558532A1 (en) * | 2004-03-10 | 2005-09-15 | Altana Pharma Ag | Novel difluoroethoxy-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors |
| BRPI0508481A (pt) * | 2004-03-10 | 2007-07-31 | Altana Pharma Ag | hidróxi-6-fenilenantridinas amido-substituìdas e seu uso como inibidores de pde4 |
| JP4960870B2 (ja) * | 2004-09-08 | 2012-06-27 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規の３−チア−１０−アザ−フェナントレン誘導体 |
| US7411093B2 (en) | 2004-12-20 | 2008-08-12 | Hoffman-La Roche Inc. | Aminocycloalkanes as DPP-IV inhibitors |
| NZ589278A (en) | 2005-03-02 | 2012-04-27 | Nycomed Gmbh | Selected salts of 6-heterocyclyl substituted hexahydrophenanthridine derivatives |
| CN102600144A (zh) | 2005-03-08 | 2012-07-25 | 奈科明有限责任公司 | 治疗糖尿病的罗氟司特 |
| US20080214536A1 (en) * | 2005-03-09 | 2008-09-04 | Nycomed Gmbh | Amido-Substituted 6-Phenylphenanthridines |
| CN101815512B (zh) | 2007-10-04 | 2013-04-24 | 弗·哈夫曼-拉罗切有限公司 | 环丙基芳基酰胺衍生物和其用途 |
| US8629274B2 (en) | 2011-12-21 | 2014-01-14 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
| UY34993A (es) | 2012-08-28 | 2014-02-28 | Janssen R & D Ireland | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b |
| PL2961732T3 (pl) | 2013-02-28 | 2017-09-29 | Janssen Sciences Ireland Uc | Sulfamoilo-aryloamidy i ich stosowanie jako leków do leczenia wirusowego zapalenia wątroby typu B |
| EP2981536B1 (en) | 2013-04-03 | 2017-06-14 | Janssen Sciences Ireland UC | N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
| LT2997019T (lt) | 2013-05-17 | 2018-11-26 | Janssen Sciences Ireland Uc | Sulfamoiltiofenamido dariniai ir jų panaudojimas kaip vaistų hepatito b gydymui |
| JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
| SG11201600522UA (en) | 2013-07-25 | 2016-02-26 | Janssen Sciences Ireland Uc | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
| AP2016009122A0 (en) | 2013-10-23 | 2016-03-31 | Janssen Sciences Ireland Uc | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
| US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| KR20160128305A (ko) | 2014-02-05 | 2016-11-07 | 노비라 테라퓨틱스, 인코포레이티드 | Hbv 감염의 치료를 위한 병용 요법 |
| MX367689B (es) | 2014-02-06 | 2019-09-02 | Janssen Sciences Ireland Uc | Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis b. |
| CA2980298A1 (en) | 2015-03-19 | 2016-09-22 | Novira Therapeutics, Inc. | Azocane and azonane derivatives and methods of treating hepatitis b infections |
| US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| AR106192A1 (es) | 2015-09-29 | 2017-12-20 | Novira Therapeutics Inc | Formas cristalinas de un agente antiviral contra la hepatitis b |
| JP2019511542A (ja) | 2016-04-15 | 2019-04-25 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | カプシド集合阻害剤を含む組み合わせ及び方法 |
| US10973801B2 (en) | 2018-03-14 | 2021-04-13 | Janssen Sciences Ireland Unlimited Company | Capsid assembly modulator dosing regimen |
| BR112021015618A2 (pt) | 2019-02-22 | 2021-10-05 | Janssen Sciences Ireland Unlimited Company | Derivados de amida úteis no tratamento da infecção pelo hbv ou doenças induzidas pelo hbv |
| US11491148B2 (en) | 2019-05-06 | 2022-11-08 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3899494A (en) * | 1970-05-13 | 1975-08-12 | Sandoz Ltd | Substituted 6-phenyl benzo-naphthyridines |
| EP0882021B1 (de) | 1996-01-31 | 2003-03-05 | ALTANA Pharma AG | Neue phenanthridine |
| US6127378A (en) | 1996-03-26 | 2000-10-03 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Phenanthridines substituted in the 6 position |
| DE59708265D1 (de) * | 1996-03-26 | 2002-10-24 | Altana Pharma Ag | Neue in 6-position substituierte phenanthridine |
| DE69719778T2 (de) | 1996-11-11 | 2004-02-05 | Altana Pharma Ag | Benzonaphthyridine als bronchialtherapeutika |
| SI0968211T1 (en) | 1997-03-07 | 2004-02-29 | Altana Pharma Ag | Tetrazole derivatives |
| JP2002502403A (ja) | 1997-06-03 | 2002-01-22 | ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング | ベンゾナフチリジン |
| DK1000035T3 (da) * | 1997-07-25 | 2003-03-17 | Altana Pharma Ag | Substituerede 6-phenylphenanthridiner |
| HUP0002510A3 (en) | 1997-07-25 | 2002-10-28 | Altana Pharma Ag | Tetrazole derivatives and pharmaceutical compositions containing them |
| US6534519B1 (en) * | 1999-01-15 | 2003-03-18 | Altana Pharma Ag | Phenanthridine-N-oxides with PDE-IV inhibiting activity |
| PT1147088E (pt) * | 1999-01-15 | 2006-05-31 | Altana Pharma Ag | 6-arilfenantridinas com actividade inibitoria da pde-iv |
| EP1147087B1 (en) * | 1999-01-15 | 2005-05-11 | ALTANA Pharma AG | Phenanthridine-n-oxides with pde-iv inhibiting activity |
-
2000
- 2000-01-12 EP EP00901534A patent/EP1147089B1/en not_active Expired - Lifetime
- 2000-01-12 CZ CZ20012248A patent/CZ300366B6/cs not_active IP Right Cessation
- 2000-01-12 WO PCT/EP2000/000172 patent/WO2000042020A1/en not_active Application Discontinuation
- 2000-01-12 RS YUP-487/01A patent/RS50297B/sr unknown
- 2000-01-12 NZ NZ512872A patent/NZ512872A/en not_active IP Right Cessation
- 2000-01-12 US US09/889,144 patent/US6476025B1/en not_active Expired - Lifetime
- 2000-01-12 SK SK980-2001A patent/SK286946B6/sk not_active IP Right Cessation
- 2000-01-12 SI SI200030806T patent/SI1147089T1/sl unknown
- 2000-01-12 HU HU0105001A patent/HU227624B1/hu not_active IP Right Cessation
- 2000-01-12 KR KR1020017008670A patent/KR100720906B1/ko not_active IP Right Cessation
- 2000-01-12 PL PL348925A patent/PL205670B1/pl unknown
- 2000-01-12 EA EA200100731A patent/EA003780B1/ru not_active IP Right Cessation
- 2000-01-12 DK DK00901534T patent/DK1147089T3/da active
- 2000-01-12 EE EEP200100350A patent/EE05105B1/xx not_active IP Right Cessation
- 2000-01-12 BR BRPI0007527-2A patent/BR0007527B1/pt not_active IP Right Cessation
- 2000-01-12 CN CNB008027951A patent/CN1152864C/zh not_active Expired - Fee Related
- 2000-01-12 EP EP05108689A patent/EP1650193A3/en not_active Withdrawn
- 2000-01-12 AU AU22896/00A patent/AU774868B2/en not_active Ceased
- 2000-01-12 DE DE60024581T patent/DE60024581T2/de not_active Expired - Lifetime
- 2000-01-12 IL IL14402600A patent/IL144026A0/xx active IP Right Grant
- 2000-01-12 TR TR2001/01938T patent/TR200101938T2/xx unknown
- 2000-01-12 CA CA002359440A patent/CA2359440C/en not_active Expired - Fee Related
- 2000-01-12 JP JP2000593588A patent/JP4653314B2/ja not_active Expired - Fee Related
- 2000-01-12 AT AT00901534T patent/ATE312081T1/de active
- 2000-01-12 ES ES00901534T patent/ES2254132T3/es not_active Expired - Lifetime
- 2000-01-12 ID IDW00200101411A patent/ID29070A/id unknown
- 2000-01-12 TR TR2005/01553T patent/TR200501553T2/xx unknown
- 2000-12-01 UA UA2001085778A patent/UA69436C2/uk unknown
-
2001
- 2001-06-04 BG BG105561A patent/BG65126B1/bg unknown
- 2001-06-14 ZA ZA200104864A patent/ZA200104864B/en unknown
- 2001-06-27 IL IL144026A patent/IL144026A/en not_active IP Right Cessation
- 2001-07-05 NO NO20013341A patent/NO320182B1/no not_active IP Right Cessation
- 2001-08-02 HR HR20010578A patent/HRP20010578A2/hr not_active Application Discontinuation
-
2002
- 2002-04-10 HK HK02102714.9A patent/HK1040997B/zh not_active IP Right Cessation
-
2006
- 2006-02-14 CY CY20061100209T patent/CY1106436T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0105001A2 (hu) | PDE-IV gátló aktivitással rendelkező fenil-fenantridinek és ezeket tartalmazó gyógyszerkészítmények | |
| MY127066A (en) | Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors. | |
| HUP0400918A2 (hu) | Pirazolin-származékok alkalmazása sejtburjánzásos betegségek megelőzésére és/vagy kezelésére szolgáló gyógyszerkészítmények előállítására | |
| JP2002534508A5 (hu) | ||
| DE60022021D1 (de) | Zubereitungen enthaltend Apomorphin und Sildenafil und ihre Verwendung zur Behandlung von erektiler Dysfunktion | |
| HUP0002510A2 (hu) | Tetrazolszármazékok és a vegyületeket tartalmazó gyógyászati készítmények | |
| BR9915552A (pt) | Pirimidinas inibidoras da reprodução do hiv | |
| HUP0401777A2 (hu) | 3H-[1,2,4]Triazolo[5,1-i]purin-5-il-aminok mint adenozin A2a receptor antagonisták és a vegyületeket tartalmazó gyógyszerkészítmények | |
| TW200514580A (en) | Adhesive preparations | |
| MY144655A (en) | Pyrimidine urea derivatives as kinase inhibitors | |
| NZ544009A (en) | Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain | |
| TW200607799A (en) | Therapeutic compounds: pyridine as scaffold | |
| TW200626592A (en) | Heterocyclic derivatives and their use as therapeutic agents | |
| KR900003154A (ko) | 우울증 치료제인 n-치환된 니코틴아미드 화합물 | |
| NZ545506A (en) | Therapeutic agents useful for treating pain | |
| HRP20040097B1 (hr) | 2-amino-4,5-trisupstituirani derivati tiazolila | |
| CA2451562A1 (en) | Piperazine compound | |
| UA86776C2 (ru) | Производные бензимидазола, фармацевтическая композиция, которая их содержит, способ их получения и применение | |
| TW200504029A (en) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
| JP2002534506A5 (hu) | ||
| HUP0303038A2 (hu) | Szubsztituált azolszármazékok mint kortikotropin releasing faktor inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| MY139676A (en) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
| GB0310726D0 (en) | Therapeutic agents | |
| SE0302570D0 (sv) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
| HUP0300402A2 (hu) | [Kinolil-(4-piperidinilidén)-metil]-benzamid-származékok fájdalom kezelésére és ezeket tartalmazó gyógyszerkészítmények |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB9A | Succession in title |
Owner name: ALTANA PHARMA AG, DE Free format text: FORMER OWNER(S): BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH., DE |
|
| HC9A | Change of name, address |
Owner name: TAKEDA GMBH, DE Free format text: FORMER OWNER(S): BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH., DE; ALTANA PHARMA AG, DE; NYCOMED GMBH, DE |
|
| MM4A | Lapse of definitive patent protection due to non-payment of fees |